A Quick and Practical Approach to Secure a Chronic Fatigue Syndrome Diagnosis: The Novel Functional Limitation Index.
Corbalán, Juan Antonio, Feltes, Gisela, Silva, Daniela et al. · Journal of clinical medicine · 2023 · DOI
Quick Summary
Researchers developed a simple test called the Functional Limitation Index (FLI) to help doctors diagnose ME/CFS more quickly and objectively. The test uses measurements from exercise testing and breathing tests to identify how much a person's physical function is impaired. In their study, the FLI successfully distinguished ME/CFS patients from healthy people and athletes with high accuracy.
Why It Matters
ME/CFS diagnosis currently relies on clinical criteria and exclusion of other conditions, creating diagnostic delays. An objective, physiologically-based parameter could accelerate diagnosis, reduce healthcare burden, and facilitate earlier intervention. This tool could improve care access for patients who often face delayed recognition of their condition.
Observed Findings
CFS patients showed significantly higher FLI scores (2.7) compared to non-CFS controls (1.2), p < 0.001.
The FLI demonstrated superior diagnostic accuracy (AUC 0.94) compared to individual spirometric variables.
Using an FLI cutoff of 1.66, sensitivity was 87.4% and specificity was 86.4%.
CFS patients demonstrated lower functional class and worse performance across all measured physical parameters.
85% of the CFS group were female compared to 25.5% of controls, suggesting potential sex-related differences in diagnosis or disease presentation.
Inferred Conclusions
The FLI provides an objective, single-day physiological parameter that can accurately distinguish ME/CFS patients from healthy controls and athletes.
The FLI may support clinical diagnosis and reduce diagnostic uncertainty in patients with suspected ME/CFS.
This index could facilitate earlier recognition and referral of ME/CFS cases in clinical practice.
Remaining Questions
Does the FLI perform equally well across different age groups, ethnic populations, and healthcare settings outside specialized referral centers?
Can the FLI predict disease severity, prognosis, or response to treatments in ME/CFS patients?
What This Study Does Not Prove
This study does not prove that the FLI measures the underlying cause of ME/CFS or that abnormal FLI is specific to ME/CFS—it only shows association in this particular patient population. The study cannot establish whether FLI changes over time or predicts treatment response. Cross-sectional design prevents determining whether FLI abnormalities precede or follow ME/CFS onset.